Cabozantinib plus fulvestrant for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Breast CancerCabozantinib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether cabozantinib in combination with fulvestrant is more effective than cabozantinib alone for treatment of hormone-receptor-positive breast cancer that has spread to bone.

Eligible Conditions
  • Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 2 years

2 years
Bone Scan Response Rate
Effects on bone and tumor markers
Overall Response Rate
Overall Survival
Progression Free Survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Cabozantinib plus fulvestrant
1 of 1

Experimental Treatment

68 Total Participants · 1 Treatment Group

Primary Treatment: Cabozantinib plus fulvestrant · No Placebo Group · Phase 2

Cabozantinib plus fulvestrantExperimental Group · 2 Interventions: Cabozantinib, Fulvestrant · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
FDA approved
Fulvestrant
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

ExelixisIndustry Sponsor
109 Previous Clinical Trials
17,940 Total Patients Enrolled
3 Trials studying Breast Cancer
54 Patients Enrolled for Breast Cancer
Massachusetts General HospitalLead Sponsor
2,699 Previous Clinical Trials
30,843,064 Total Patients Enrolled
78 Trials studying Breast Cancer
125,450 Patients Enrolled for Breast Cancer
Steven J Isakoff, MD, PhDPrincipal InvestigatorMassachusetts General Hospital

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: